GLP-1RA and Precision Medicine Precision medicine strategies are evolving to incorporate genetic, metabolic, and clinical biomarkers to optimize GLP-1 RA therapy, aiming to maximize efficacy and minimize adverse effects
collapse Signs of sepsis: high fever or very low temperature, rapid breathing, confusion, or feeling extremely unwell following an injection Severe hypoglycaemia with loss of consciousness or inability to swallow Severe chest pain or significant difficulty breathing Contact your GP or a healthcare professional promptly if you experience: Injection site reactions such as persistent redness, swelling, warmth, or pain, which may indicate infection or an inflammatory response Systemic symptoms including fever, chills, or malaise following administration Gastrointestinal symptoms such as severe or persistent nausea, vomiting, or abdominal pain these are known effects associated with GLP-1 receptor agonism and may require clinical assessment [15] [6] Symptoms of hypoglycaemia shakiness, sweating, confusion, or palpitations particularly if retatrutide is being used alongside other glucose-lowering agents Cardiovascular symptoms such as a rapid or irregular heartbeat Report suspected side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk
These are not situations to manage by adjusting your own dose
This hormone helps regulate blood sugar by increasing insulin production, slowing gastric emptying, and reducing appetite
Semaglutide, other GLP-1 receptor agonists continue taking the world by storm GLP-1 receptor agonists are now being used to treat obese and overweight patients throughout the United States
Back Dupr, J (26 Sept 1964) 'An intestinal hormone affecting glucose disposal in man', The Lancet , 672-73
